Abstract:Background: The outbreak of coronavirus disease 2019 (COVID-19) in Wuhan City, China spreads rapidly since December, 2019. Most patients show mild symptoms, but some of them develop into severe disease. There is currently no specific medication. The purpose of this study is to explore changes of markers in peripheral blood of severe COVID-19 patients, which may be of value in disease monitoring. Methods: Clinical data of patients with nonsevere and severe type COVID-19 diagnosed by laboratory test in our institution were collected. The relationship between peripheral blood cells and cytokines, clinical manifestation and outcome was analyzed. Results: A total of 69 severe type COVID-19 patients were included. On admission, the median age of severe cases was 56-year old, with 52.17% of female patient. The most common symptoms were fever (79.72%), coughing (63.77%), shortness of breath (57.97%) and fatigue (50.72%). Diarrhea is less common. The most common comorbidity is hypertension. Upon admission, the proportion of bilateral pulmonary involvement or interstitial pneumonia evidenced by CT imaging in severe cases was 60.87% and 27.54%, respectively. Compared with patients with nonsevere disease, those with severe disease showed lymphocytopenia. Elevated level of lactate dehydrogenase (LDH), C-reactive protein (CRP), ferritin and D-dimer was found in most cases. Two patients (2.9%) needed transfer to the intensive care unit. Baseline immunological parameters and most of the inflammatory parameters were basically within the normal range. However, baseline IL-6 was significantly increased in severe type which is closely related to the maximal body temperature during hospitalization and CT findings. Baseline IL-6 was also significantly related to the increase of baseline level of CRP, LDH, ferritin and D-dimer. The increase of baseline IL-6 level suggests that it may positively correlate with the severity of COVID-19. Among the 30 severe type patient whose level of IL-6 was assessed before and after treatment, significant decrease in IL-6 and improved CT assessment was found in 25 patients after treatment. Whereas the IL-6 level was further increased in 3 cases, which was closely related to the progression of pneumonia. It is suggested that IL-6 may be used as a biomarker for disease monitoring in severe COVID-19 patients. Conclusion: On admission, the baseline level of IL-6, CRP, LDH and ferritin was closely related to the severity of COVID-19, and the high level of IL-6 was significantly related to the clinical manifestation of severe type patients. The decrease of IL-6 was closely related to treatment effectiveness, while the increase of IL-6 indicated disease progression. Collectively, the dynamic change of IL-6 level can be used as a marker for disease monitoring in patients with severe COVID-19.Funding Statement: This work was supported by the National Natural Science Foundation of China (No. 81602696 to TL) and Science and Technology Major Project of China (No.2018ZX10302204-002-003).Declaration of Interests: All authors declare no competing interests.Ethics Approval Statement: This study was approved by the Research Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology. Written consent was obtained from patients before the enrollment.

The Monocyte Chemotactic Protein 1 as a Potential Indicator for SARS-CoV-2 Infected Mild COVID-19 Patients

Higher expression of monocyte chemotactic protein 1 in mild COVID-19 patients might be correlated with inhibition of Type I IFN signaling

IP-10 and MCP-1 As Biomarkers Predicting Disease Severity of COVID-19

Serum IL-6 and Procalcitonin Are Two Promising Novel Biomarkers for Evaluating the Severity of COVID-19 Patients.

Evaluation of Chemokines and Cytokines as Biomarkers for Disease Severity in COVID-19-Infected Patients

Serum Cytokine and Chemokine Profile in Relation to the Severity of Coronavirus Disease 2019 in China

IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19

Identification of Monocytes Associated with Severe COVID-19 in the PBMCs of Severely Infected patients Through Single-Cell Transcriptome Sequencing

Analysis of the Dynamic Relationship Between Immune Profiles and the Clinical Features of Patients with COVID-19

Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19

Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2 infection is associated with disease severity and fatal outcome

Frontline Science: COVID-19 Infection Induces Readily Detectable Morphologic and Inflammation-Related Phenotypic Changes in Peripheral Blood Monocytes

Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP)

Changes of serum IL‐10, IL‐1β, IL‐6, MCP‐1, TNF‐α, IP‐10 and IL‐4 in COVID‐19 patients

Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease

Kinetics of CD169, HLA-DR, and CD64 expression as predictive biomarkers of SARS-CoV2 outcome

Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors

Serum Soluble ST2 As a Novel Biomarker Reflecting Inflammatory Status and Disease Severity in Patients with COVID-19

Novel serological biomarkers for inflammation in predicting disease severity in patients with COVID-19

Serum Protein Profiling Reveals a Landscape of Inflammation and Immune Signaling in Early-stage COVID-19 Infection

The Potential Role of IL-6 in Monitoring Coronavirus Disease 2019

The Monocyte Chemotactic Protein 1 as a Potential Indicator for SARS-CoV-2 Infected Mild COVID-19 Patients&nbsp;